• Demonstrating an integrated AI and synthetic biology platform that routinely achieves high clonal titers across antibody modalities, from mAbs to complex multispecifics
• Highlighting model-guided process development using a hybrid AI/mechanistic model to drive improved performance
• Case studies spanning vector design, cell line development, and bioprocess optimization showing how computational methods reduce empirical iteration and accelerate manufacturing readiness